SEOUL, South Korea, June 3, 2026 /PRNewswire/ -- MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced today that it has secured the FDA's agreement to conduct a single pivotal Phase 3 study for CARTISTEM® in the U.S. This milestone marks a...
Hence then, the article about medipost secures fda agreement on single pivotal phase 3 study with confirmatory evidence bla filing strategy for cartistem in the u s was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S. )
Also on site :
- 3 shot at Sam Yeto High School graduation on Fairfield High campus, officials say
- Is Hungary about to give Ukraine the EU green light?
- Gunfire erupts in Mogadishu before protests against Somali president’s rule